Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxetacaine is a potent local anesthetic and antacid used primarily for the relief of pain associated with gastrointestinal conditions such as gastritis, peptic ulcer disease, heartburn, esophagitis, and hiatus hernia. It is typically administered orally in combination with antacids (such as aluminum hydroxide and magnesium hydroxide) to provide both mucosal anesthesia and acid neutralization. Oxetacaine acts by inhibiting gastric acid secretion through suppression of gastrin secretion and exerts a strong local anesthetic effect on the gastric mucosa by blocking nerve conduction via inhibition of sodium ion permeability in nerve membranes. Its unique chemical properties allow it to remain effective even in acidic environments where other local anesthetics may degrade. Oxetacaine is reported to be significantly more potent than lignocaine or cocaine as a local anesthetic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxetacaine.